We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
0
0 active
Approvals
4
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
FDA
Food and Drug Administration
- UPS commits $48 million to expand temperature-controlled freight cross-dock facilities across 27 locations in Europe, Asia, and the Americas. - The investment targets the growing $39.1 billion temperature-sensitive biologics market, driven by GLP-1 injectables, cell and gene therapies, and mRNA platforms. - Temperature control failures account for 50% of global vaccine waste and cost an estimated $35 billion annually, according to the World Health Organization. - The expansion strengthens UPS's end-to-end cold chain capabilities as the company's healthcare portfolio reached $3 billion in quarterly revenue for the first time.
